Epstein-barr virus nuclear antigen-2 detection and typing in immunocompromised children correlated with lymphoproliferative disorder biopsy findings

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 3, 2008, Pages 186-191

  Mendes, Thiago Marques ^a   de Oliveira, Léa Campos ^a   Yamamoto, Lídia ^a   Del Negro, Gilda Maria Barbaro ^a   Okay, Thelma Suely ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

EBNA 2; EBV genotyping; EBV PCR; EBVA; Infectious mononucleosis; Lymphoproliferative disorder

Indexed keywords

DNA; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNE HEPATITIS; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD SAMPLING; CELL IMMORTALIZATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DNA DETERMINATION; EPSTEIN BARR VIRUS; FEMALE; GENE AMPLIFICATION; HEART TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INFECTIOUS MONONUCLEOSIS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NEPHRITIS; PATHOGENESIS; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREVALENCE; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; TUMOR BIOPSY; VIRUS IDENTIFICATION; VIRUS REACTIVATION; VIRUS TYPING;

EID: 54349092880     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702008000300005     Document Type: Article

References (34)

1. McClain K.L. Epstein-Barr virus and HIV-associated diseases. Biomed Pharmacother 2001;55(7):348-52.
2. Chand D.H., Southerland S.M., Cunningham R.J. 3rd. Tacrolimus: the good, the bad and the ugly. Pediatr Transplant 2001;5(1):32-6.
3. Fuentes-Pananá E., Ling P.D. Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation. Journal of Virology 1998;72(1):693-700.
4. Grabusic K., Maier S., Hartmann A., et al. The CR4 region of EBNA-2 confers viability of Epstein-Barr virus-transformed B cells by CBF-1-independent signaling. J Gen Virol 2006; 87(11): 3169-3176.
5. Cohen JL, Wang F, Mannick J, et al. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989;86:9558-62.
6. Rabson M., Gradoville L., Heston L., et al. Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J Virol 1982;44:834-44.
7. Sculley T.B., Sculley D.G., Pope J.H., et al. Epstein-Barr virus nuclear antigens 1 and 2 in Burkitt lymphoma cell lines containing either A or B - type virus. Intervirology 1988;29(2):77-85.
8. Rickinson A.B., Young L.S., Rowe M. Influence of the Epstein-barr virus nuclear antigen EBNA-2 on the growth phenotype of virus-transformed B cells. J Virol 1987;61:1310-7.
9. Borisch B., Finke J., Hennig I., et al. Distribution and localization of Epstein-Barr virus subtypes A and B in AIDS-related lymphomas and lymphatic tissue of HIV-positive patients. J Pathol 1992; 168:229-36.
10. Aguirre A.J., Robertson E.S. Characterization of intertypic recombinants of the Epstein-Barr virus from the body-cavitybased lymphomas cell lines BC-1 and BC-2. Virology 1999;264(2):359-69.
11. Ometto L., Menin C., Masiero S., et al. Molecular profile of Eptein- Barr Virus in Human Immunodeficiency Virus Type 1-related lymphadenopathies and lymphomas. Blood 1997;90(1):313-22.
12. Buisson M., Morand P., Genoulaz O., et al. Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection. J Gen Virol 1994;75:431-7.
13. Aitken C., Sengupta S.K., Aedes C., et al. Heterogeneity within the Epstein-Barr virus Nuclear Antigen 2 gene in different strains of Epstein-Barr virus. J Gen Virol 1994;75:95.
14. Maier S., Staffler G., Hartmann A., et al. Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol 2006;80(19):9761-71.
15. Bark-Jones S.J., Webb H.M., West M.J. EBV EBNA-2 stimulates CDK-9-dependent transcription and RNA polymerase II phosphorylation on serine 5. Oncogene 2006;25(12):1775-85.
16. Tobollik S., Meyer L., Buettner M., et al. Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth. Blood 2006;108(12):3859-64.
17. Pegman P.M., Smith S.M., D'Souza B.N., et al. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF-1/RBJ kappa-dependent pathway. J Virol 2006;80(16):8133-44.
18. Telenti A., Marshall W.F., Smith T.F. Detection of Epstein-Barr virus by polymerase chain reaction. J Clin Microbiol 1990;28(10):2187-90.
19. Miller A.S., Dykes D.D., Polensky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
20. Araujo I., Foss H.-D., Bittencourt A., et al. Expression of Epstein-Barr vírus gene products in Burkitt's lymphoma in Northeast Brazil. Blood 1996;87(12):5279-86.
21. Araujo I., Bittencourt A.L., Barbosa H.S., et al. The high frequency of EBV infection in pediatric Hodgkin Lymphoma is related to the classical type in Bahia, Brazil. Virchows Arch 2006;449(3):315-9.
22. Hassan R., White L.R., Stefanoff C.G., et al. Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol 2006;1:1-7.
23. Norin S., Kimby E., Ericzon B.G., et al. Posttransplant lymphoma: a single-center experience of 500 liver transplantation. Med Oncol 2004;21(3):273-84.
24. Okano M. Epstein-Barr virus in patients with immunodeficiency disorders. Biomed Pharmacother 2001;55(7):353-61.
25. Canioni D., Jabado N., MacIntyre E., et al. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology 2001;38(2):146-59.
26. Kondo N., Inoue R., Orii T. Responses of lymphocytes to Epstein-Barr vírus in patients with primary immunodeficiencies. J Investig Allergol Clin Immunol 1994;4(4):182-4.
27. Kanegane H., Miyawaki T., Iwai K., et al. Acute Thrombocytopenic Purpura associated with primary Epstein-Barr virus infection. Acta Pediatr Jpn 1994;36(4):423-6.
28. Yenicesu I., Yetgin S., Ozyürek E., et al. Virus-associated immune thrombocytopenic purpura in childhood. Pediatr Hematol Oncol 2002; 19(6):433-7.
29. Araya C.E., González-Peralta R.P., Skoda-Smith S., et al. Systemic Epstein-Barr virus infection associated with membranous nephropathy in children. Clin Nephrol 2006;65(3):160-4.
30. Shimage M., Kawahara K., Harada S., et al. Expression of Epstein-Barr virus in renal cell carcinoma. Oncol Rep 2007;18(1):41-6.
31. Incaprera M., Rindi L., Bazzichi A., et al. Potential role of Epstein-Barr virus in systemic lupus erythematosus autoiimunity. Clin Exp Rheumatol 1998;16(3):289-94.
32. Kunimoto M., Tamura S., Tabata T., et al. One-step typing of Epstein-Barr vírus by polymerase chain reaction: predominance of type 1 virus in Japan. J Gen Virol 1992;73:455-61.
33. Peh S.C., Kim L.H., Poppema S. Frequent presence of subtype A virus in Epstein-Barr virus-associated malignancies. Pathology 2002; 34(5):446-50.
34. Okano M., Gross T.G. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients. Expert Rev Anti Infect Ther 2007;5(3):403-13.